Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 1
2011 2
2012 2
2013 4
2014 9
2015 7
2016 6
2017 20
2018 17
2019 23
2020 58
2021 57
Text availability
Article attribute
Article type
Publication date

Search Results

187 results
Results by year
Filters applied: . Clear all
Page 1
Developing mRNA-vaccine technologies.
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Schlake T, et al. RNA Biol. 2012 Nov;9(11):1319-30. doi: 10.4161/rna.22269. Epub 2012 Oct 12. RNA Biol. 2012. PMID: 23064118 Free PMC article. Review.
Taken together, mRNA presents a promising vector that may well become the basis of a game-changing vaccine technology platform. Here, we outline the current knowledge regarding different aspects that should be considered when developing an mRNA-based vacci
Taken together, mRNA presents a promising vector that may well become the basis of a game-changing vaccine technology platform …
Recent advances in mRNA vaccine technology.
Pardi N, Hogan MJ, Weissman D. Pardi N, et al. Curr Opin Immunol. 2020 Aug;65:14-20. doi: 10.1016/j.coi.2020.01.008. Epub 2020 Mar 31. Curr Opin Immunol. 2020. PMID: 32244193 Review.
Messenger RNA (mRNA) vaccines represent a relatively new vaccine class showing great promise for the future. This optimism is built on recently published studies demonstrating the efficacy of mRNA vaccines in combatting several types of cancer and infectious …
Messenger RNA (mRNA) vaccines represent a relatively new vaccine class showing great promise for the future. This optimism is …
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. Maruggi G, et al. Mol Ther. 2019 Apr 10;27(4):757-772. doi: 10.1016/j.ymthe.2019.01.020. Epub 2019 Feb 7. Mol Ther. 2019. PMID: 30803823 Free PMC article. Review.
Thanks to these data, together with the potential for generic, low-cost manufacturing processes and the completely synthetic nature, the prospects for mRNA vaccines are very promising. In addition, mRNA vaccines have the potential to streamline vaccine discov …
Thanks to these data, together with the potential for generic, low-cost manufacturing processes and the completely synthetic nature, the pro …
A Thermostable mRNA Vaccine against COVID-19.
Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, Guo Y, Sun SH, Fan H, Zu SL, Chen Q, He Q, Cao TS, Huang XY, Qiu HY, Nie JH, Jiang Y, Yan HY, Ye Q, Zhong X, Xue XL, Zha ZY, Zhou D, Yang X, Wang YC, Ying B, Qin CF. Zhang NN, et al. Cell. 2020 Sep 3;182(5):1271-1283.e16. doi: 10.1016/j.cell.2020.07.024. Epub 2020 Jul 23. Cell. 2020. PMID: 32795413 Free PMC article.
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge …
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all appro …
mRNA vaccine delivery using lipid nanoparticles.
Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. Reichmuth AM, et al. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Ther Deliv. 2016. PMID: 27075952 Free PMC article. Review.
mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluated in clinical trials for cancer immunotherapy applications, but also have great potential as prophylactic vaccines. Efficient delivery of
mRNA vaccines elicit a potent immune response including antibodies and cytotoxic T cells. mRNA vaccines are currently evaluate
mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.
Xu S, Yang K, Li R, Zhang L. Xu S, et al. Int J Mol Sci. 2020 Sep 9;21(18):6582. doi: 10.3390/ijms21186582. Int J Mol Sci. 2020. PMID: 32916818 Free PMC article. Review.
It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. At the same time, some suggestions for future mRNA vaccine development about storage methods, safety concerns, and personal …
It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosi …
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies.
Liu MA. Liu MA. Vaccines (Basel). 2019 Apr 24;7(2):37. doi: 10.3390/vaccines7020037. Vaccines (Basel). 2019. PMID: 31022829 Free PMC article. Review.
This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technologies. While both have been under development since the 1990s, in recent years, significant excitement has turned to mRNA despite the …
This review provides a comparison of the theoretical issues and experimental findings for plasmid DNA and mRNA vaccine technol …
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, Neuzil KM, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Jackson LA, et al. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. N Engl J Med. 2020. PMID: 32663912 Free PMC article. Clinical Trial.
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion S …
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an internat …
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5. Nature. 2020. PMID: 32756549 Free PMC article.
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusi …
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-1 …
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Stevens LJ, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. bioRxiv. 2020 Jun 11:2020.06.11.145920. doi: 10.1101/2020.06.11.145920. Preprint. bioRxiv. 2020. PMID: 32577634 Free PMC article. Updated.
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. ...Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized …
A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. ...Using this established immunogen design, the r …
187 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page